
News


Consequences of Poor Sleep in the Elderly

Prevalence of Insomnia Disorder With Age

Defining and Diagnosing Insomnia Disorder

FDA Rejects Duchenne Muscular Dystrophy Drug Golodirsen, Citing Safety Concerns
The regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center will offer further insights on narcolepsy at the upcoming International Congress on the Future of Neurology, September 27-28, 2019 in New York City.

Pfizer Recalls Relpax for Migraine Due to Potential Microbiological Contamination
Those with an existing inventory of eletriptan hydrobromide 40 mg tablets, lots AR5407 and CD4565, should stop use and distribution, and quarantine immediately.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Reisa Sperling, MD.

Phase 3 Trial of Vutrisiran Evaluates Potential Therapy for Hereditary Transthyretin-Mediated Amyloidosis
The investigational candidate is the subject of a phase 3 study assessing efficacy and safety in adults with hATTR amyloidosis with transthyretin mutation.

Trends in Migraine Care Reveal Treatment Gaps and Education Barriers
The director of the MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the ongoing efforts in drug development and what the ideal future may hold for migraine medicine.

Alzheimer Disease: Take Home Messages and Parting Advice

Future Investigation and Use of Amyloid-Targeted Agents in AD

Amyloid-Targeted Strategies in Alzheimer Disease Management

Alzheimer Disease: Evolving Blood Tests and Protofibrils

Goals of Therapy With the Modern Armamentarium for AD

Impacting Alzheimer Disease With Brain Health Strategies

Imaging's Role in the Diagnosis of Alzheimer Disease

Genetic Testing Recommendations in Alzheimer Disease

Early Diagnosis of AD: Importance and Assessment Scales

Alzheimer Disease: Cooperating With PCPs to Make a Diagnosis

Causes and Detection of Alzheimer Disease

The Symbiotic Relationship of Artificial Intelligence and Neurology
The associate chief of the MS division and professor of neurology at the University of Pennsylvania described the relationship between artificial intelligence and medicine, and how he sees it evolving in the future.

Dementia Emergency Department Use Can Be Reduced With Specialized Telemedicine
The professor of emergency medicine at the University of Wisconsin-Madison School of Medicine and Public Health discussed the impact that telemedicine, conducted in senior living communities, can have on emergency department visits for individuals with dementia.

Impact of Caregiver Depression on Patients With Dementia, CAG Repeat Length Predicts Huntington Disease Decline, Novel Oral CBD Formulation Effective in Epilepsy
Neurology News Network for the week ending August 17, 2019.

Higher Incident Dementia Associated With Mid- to Late-Life Blood Pressure
The findings of a pair of recent studies have suggested that the presence and chronicity of hyper- and hypotension in mid- and late-life increases the risk of incident dementia, and that intensive blood pressure intervention can, although modestly, impact cerebral small vessel ischemic disease.

Annette Langer-Gould, MD, PhD: Lowering Postpartum MS Relapse Rates With Breastfeeding
The regional lead in clinical and translational neuroscience at Kaiser Permanente discussed subgroup findings from a study of pregnancy in women with MS which suggested that breastfeeding in the postpartum period can drastically decrease the risk of disease relapse.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado spoke about patient interest in cannabidiol after the FDA approval of Epidiolex, and what remains to be done to perfect its use in epilepsy.

Pitolisant Offers Important Risk-Benefit Profile for Patients With Narcolepsy
Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.

Alzheimer Cognition Monitoring With 18-FDG PET Tracer Superior to Florbetapir
While both 18F-FDG and 18F-florbetapir can discriminate those with dementia from healthy controls, the correlation to cognitive scores are much stronger with 18F-FDG.

The postdoctoral scholar at the University of California San Francisco discussed the findings from her study that gives comprehensive insight into prevalence and organ associations of vasculitic neuropathy.